AU2080201A - Treatment of addiction disorders - Google Patents

Treatment of addiction disorders

Info

Publication number
AU2080201A
AU2080201A AU20802/01A AU2080201A AU2080201A AU 2080201 A AU2080201 A AU 2080201A AU 20802/01 A AU20802/01 A AU 20802/01A AU 2080201 A AU2080201 A AU 2080201A AU 2080201 A AU2080201 A AU 2080201A
Authority
AU
Australia
Prior art keywords
treatment
addiction disorders
addiction
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20802/01A
Inventor
Stephen Paul Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CINCINNATI THE, University of
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2080201A publication Critical patent/AU2080201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
AU20802/01A 1999-12-10 2000-12-08 Treatment of addiction disorders Abandoned AU2080201A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17010499P 1999-12-10 1999-12-10
US60170104 1999-12-10
PCT/US2000/033444 WO2001041763A1 (en) 1999-12-10 2000-12-08 Treatment of addiction disorders

Publications (1)

Publication Number Publication Date
AU2080201A true AU2080201A (en) 2001-06-18

Family

ID=22618564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20802/01A Abandoned AU2080201A (en) 1999-12-10 2000-12-08 Treatment of addiction disorders

Country Status (2)

Country Link
AU (1) AU2080201A (en)
WO (1) WO2001041763A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1685838A1 (en) * 2000-08-16 2006-08-02 Pharmacia & Upjohn Company LLC Compounds for the treatment of addictive disorders
DE10137162A1 (en) * 2001-07-30 2003-02-20 Hexal Ag Transdermal therapeutic system for administration of pramipexole or ropinirole for treating Parkinson's disease, comprises backing layer, reservoir, semipermeable membrane, adhesive layer and protecting layer
DE10148233A1 (en) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Compounds to reduce excessive food intake
SI21351A (en) 2002-12-17 2004-06-30 LEK farmacevtska dru�ba d.d. Treatment of dependence on psychostimulants
DE10312809A1 (en) * 2003-03-21 2004-09-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexole to reduce excessive food intake in children
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

Also Published As

Publication number Publication date
WO2001041763A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU2002348135A1 (en) Methods for the treatment of addiction
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
AU3791601A (en) Treatment of coal
AU6910600A (en) Methods for the treatment of mental disorders
AU1356201A (en) Treatment of hyperproliferative disorders
AUPR074500A0 (en) Treatment of t cell disorders
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU3896900A (en) Treatment of pain
AU2001239510A1 (en) Treatment of renal disorders
GB9926968D0 (en) Treatment of neurological disorders
AU5547000A (en) Novel treatment
AU7106300A (en) Treatment of skin disorders
AU7750100A (en) Method for the treatment of obesity
AU2080201A (en) Treatment of addiction disorders
AU4556800A (en) Novel treatment
AU3899100A (en) Treatment of hyperactivity disorders
AU2566201A (en) Compounds and methods for the treatment of pain
AU1405001A (en) Treatment of diseases
AU5646300A (en) Methods of stimulating angiogenesis
AU3753500A (en) Methods of treating fibrinogen-related disorders
AU4598400A (en) Method of treatment
AU2382601A (en) Novel method of treatment
AU2001253560A1 (en) Methods of treatment
AU2420201A (en) Compounds and methods for the treatment of pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase